4.6 Article

Mice Lacking Inositol 1,4,5-Trisphosphate Receptors Exhibit Dry Eye

期刊

PLOS ONE
卷 9, 期 6, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0099205

关键词

-

资金

  1. Japanese Ministry of Education, Culture, Sports, Science and Technology [20659272]
  2. Nagao Memorial Fund
  3. Moritani Scholarship Foundation
  4. JSPS KAKENHI [20220007]
  5. Japan Science and Technology Agency
  6. Grants-in-Aid for Scientific Research [20659272] Funding Source: KAKEN

向作者/读者索取更多资源

Tear secretion is important as it supplies water to the ocular surface and keeps eyes moist. Both the parasympathetic and sympathetic pathways contribute to tear secretion. Although intracellular Ca2+ elevation in the acinar cells of lacrimal glands is a crucial event for tear secretion in both the pathways, the Ca2+ channel, which is responsible for the Ca2+ elevation in the sympathetic pathway, has not been sufficiently analyzed. In this study, we examined tear secretion in mice lacking the inositol 1,4,5-trisphosphate receptor (IP3R) types 2 and 3 (Itpr2(-/-); Itpr3(-/-) double-knockout mice). We found that tear secretion in both the parasympathetic and sympathetic pathways was abolished in Itpr2(-/-); Itpr3(-/-) mice. Intracellular Ca2+ elevation in lacrimal acinar cells after acetylcholine and epinephrine stimulation was abolished in Itpr2(-/-); Itpr3(-/-) mice. Consequently, Itpr2(-/-); Itpr3(-/-) mice exhibited keratoconjunctival alteration and corneal epithelial barrier disruption. Inflammatory cell infiltration into the lacrimal glands and elevation of serum autoantibodies, a representative marker for Sjogren's syndrome (SS) in humans, were also detected in older Itpr2(-/-); Itpr3(-/-) mice. These results suggested that IP(3)Rs are essential for tear secretion in both parasympathetic and sympathetic pathways and that Itpr2(-/-); Itpr3(-/-) mice could be a new dry eye mouse model with symptoms that mimic those of SS.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Ophthalmology

Eyelid blood vessel and meibomian gland changes in a sclerodermatous chronic GVHD mouse model

Fan Yang, Isami Hayashi, Shinri Sato, Yumiko Saijo-Ban, Mio Yamane, Masaki Fukui, Eisuke Shimizu, Jingliang He, Shinsuke Shibata, Shin Mukai, Kazuki Asai, Mamoru Ogawa, Yuqing Lan, Qingyan Zeng, Akito Hirakata, Kazuo Tsubota, Yoko Ogawa

Summary: The study revealed that sclerodermatous chronic graft-versus-host disease (cGVHD) can lead to pathological changes in blood vessels and meibomian glands (MGs) in the eyelids, including endothelial injury and activation, neovascularization, fibrotic changes, immune cell infiltration, and necrosis and apoptosis of MG basal cells.

OCULAR SURFACE (2022)

Article Rheumatology

Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update

Daniel Aletaha, Andreas Kerschbaumer, Kastriot Kastrati, Christian Dejaco, Maxime Dougados, Iain B. McInnes, Naveed Sattar, Tanja A. Stamm, Tsutomu Takeuchi, Michael Trauner, Desiree van der Heijde, Marieke Voshaar, Kevin L. Winthrop, Angelo Ravelli, Neil Betteridge, Gerd-Ruediger R. Burmester, Johannes W. J. Bijlsma, Vivian Bykerk, Roberto Caporali, Ernest H. Choy, Catalin Codreanu, Bernard Combe, Mary K. Crow, Maarten de Wit, Paul Emery, Roy M. Fleischmann, Cem Gabay, Merete Lund Hetland, Kimme L. Hyrich, Annamaria Iagnocco, John D. Isaacs, Joel M. Kremer, Xavier Mariette, Peter Merkel, Eduardo F. Mysler, Peter Nash, Michael T. Nurmohamed, Karel Pavelka, Gyula Poor, Andrea Rubbert-Roth, Hendrik Schulze-Koops, Anja Strangfeld, Yoshiya Tanaka, Josef S. Smolen

Summary: This paper is an updated consensus document on the medical use of IL-6 pathway inhibition in the treatment of inflammatory diseases. The document provides comprehensive consensus statements based on systematic literature research and expert opinion, covering various aspects of IL-6 pathway inhibitors, including dosing, indications, and clinical considerations.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

Efficacy and safety of anti-TNF multivalent NANOBODY® compound 'ozoralizumab' without methotrexate co-administration in patients with active rheumatoid arthritis: A 52-week result of phase III, randomised, open-label trial (NATSUZORA trial)

Yoshiya Tanaka, Masafumi Kawanishi, Megumi Nakanishi, Hironori Yamasaki, Tsutomu Takeuchi

Summary: Subcutaneous ozoralizumab treatment for 52 weeks demonstrated significant therapeutic effects and acceptable tolerability in patients with active rheumatoid arthritis.

MODERN RHEUMATOLOGY (2023)

Article Ophthalmology

Multicenter prospective validation study for international chronic ocular graft-versus-host disease consensus diagnostic criteria

Yoko Ogawa, Reza Dana, Stella Kim, Sandeep Jain, Mark I. Rosenblatt, Victor L. Perez, Janine A. Clayton, Monica Alves, Eduardo Melani Rocha, Francisco Amparo, Kyoung Yul Seo, Yan Wang, Joanne Shen, Joo Youn Oh, Murugesan Vanathi, Sridevi Nair, Kyung-Sun Na, Anjo Riemens, Kimberly Sippel, Matias Soifer, Shudan Wang, Marilia Trindade, Mee Kum Kim, Chang Ho Yoon, Ryuichiro Yagi, Ryo Hiratsuka, Mamoru Ogawa, Eisuke Shimizu, Yasunori Sato, Stephen Pflugfelder, Kazuo Tsubota

Summary: The study validates the consistency between ICCGVHD and NIH2014 in the diagnosis of chronic ocular GVHD. ICCGVHD score =6 can be useful in diagnosing ocular GVHD with or without systemic GVHD for clinical research.

OCULAR SURFACE (2022)

Review Rheumatology

Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

Sytske Anne Bergstra, Alexandre Sepriano, Andreas Kerschbaumer, Desiree van der Heijde, Roberto Caporali, Christopher John Edwards, Patrick Verschueren, Savia de Souza, Janet E. Pope, Tsutomu Takeuchi, Kimme L. Hyrich, Kevin L. Winthrop, Daniel Aletaha, Tanja A. Stamm, Jan W. Schoones, Josef S. Smolen, Robert B. M. Landewe

Summary: This systematic literature review examines the efficacy, duration of use, and safety of glucocorticoids (GCs) in the management of rheumatoid arthritis (RA). The study confirms the effectiveness of GCs in treating RA, with most patients able to stop GCs within 12-24 months. However, the use of GCs also carries well-known safety risks, including osteoporotic fractures, serious infections, diabetes, and mortality.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

Irreversible covalent Bruton's tyrosine kinase inhibitor, TAS5315 versus placebo in rheumatoid arthritis patients with inadequate response to methotrexate: a randomised, double-blind, phase IIa trial

Tsutomu Takeuchi, Sakae Tanaka, Mitsuru Murata, Yoshiya Tanaka

Summary: This study aimed to evaluate the efficacy and safety of TAS5315 in Japanese patients with refractory rheumatoid arthritis. The results showed numerical differences in disease activity improvement rates between the TAS5315 group and the placebo group at week 12, but the primary endpoint was not achieved. However, TAS5315 demonstrated advantages in disease activity and biomarker improvement, as well as higher risk of bleeding events within 36 weeks. Therefore, a risk-benefit analysis of TAS5315 should be considered.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post-hoc analysis of clinical trials

Yoshiya Tanaka, Tsutomu Takeuchi, Derek Haaland, Stephen Hall, Nevsun Inanc, Zhanguo Li, Ricardo M. M. Xavier, Carlos Cara, Nicola Tilt, Peter C. C. Taylor

Summary: This study assessed the efficacy of Certolizumab pegol (CZP) in patients with early and established rheumatoid arthritis (RA) and found that it was effective in reducing symptoms in patients with different rheumatoid factors (RF) levels. CZP may be considered as a treatment option for RA.

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2023)

Article Rheumatology

Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)

Peter C. Taylor, Michael E. Weinblatt, Iain B. McInnes, Tatsuya Atsumi, Vibeke Strand, Tsutomu Takeuchi, Marguerite Bracher, David Brooks, John Davies, Christopher Goode, Anubha Gupta, Sumanta Mukherjee, Ciara O'Shea, Didier Saurigny, Lorrie A. Schifano, Celia Shelton, Julia E. Smith, Millie Wang, Reena Wang, Sarah Watts, Roy M. Fleischmann

Summary: This study investigated the efficacy and safety of otilimab in patients with active rheumatoid arthritis. The results showed that otilimab did not achieve the primary endpoint of ACR20 and did not demonstrate non-inferiority to sarilumab in this patient population.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

Effectiveness and safety of rituximab in special types of rheumatoid arthritis

Satoshi Takanashi, Yasushi Kondo, Shuntaro Saito, Jun Kikuchi, Hironari Hanaoka, Tsutomu Takeuchi, Yuko Kaneko

Summary: Rituximab is an effective treatment option for patients with lymphoproliferative disorder and rheumatoid vasculitis, showing significant improvements in disease activity scores and reduction in prednisolone dosage, with a good safety profile.

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2023)

Article Pharmacology & Pharmacy

Population Pharmacokinetics of Ozoralizumab in Patients with Rheumatoid Arthritis

Tsutomu Takeuchi, Yukihiro Chino, Yoko Mano, Masafumi Kawanishi, Yuri Sato, Saeko Uchida, Yoshiya Tanaka

Summary: A population pharmacokinetic (PK) model was developed to assess the effects of potential PK covariates on the PK of ozoralizumab. The model adequately described the PK of ozoralizumab in Japanese patients with rheumatoid arthritis, and body weight was found to have the greatest impact on its PK.

JOURNAL OF CLINICAL PHARMACOLOGY (2023)

Article Rheumatology

Effect of the extended dosing interval of anti-TNF-α NANOBODY® compound ozoralizumab in patients with low disease activity rheumatoid arthritis

Tsutomu Takeuchi, Megumi Nakanishi, Masafumi Kawanishi, Hironori Yamasaki, Yoshiya Tanaka

Summary: This article evaluates the efficacy and safety of extending the dosing interval of ozoralizumab from every 4 weeks to every 8 weeks in patients with rheumatoid arthritis (RA). The results indicate that extending the dosing interval is effective and well tolerated in patients maintaining a disease activity score below 3.2.

MODERN RHEUMATOLOGY (2023)

Editorial Material Rheumatology

25 years of biologic DMARDs in rheumatology

Marc Feldmann, Ravinder N. Maini, Enrique R. Soriano, Vibeke Strand, Tsutomu Takeuchi

Summary: In this Viewpoint article, five rheumatology researchers discuss how biologic therapy has transformed clinical practice and reflect on their own experiences, past and current challenges, and the future prospects of biologic drugs.

NATURE REVIEWS RHEUMATOLOGY (2023)

Article Rheumatology

Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials

Tsutomu Takeuchi, Yukihiro Chino, Masafumi Kawanishi, Megumi Nakanishi, Hirotaka Watase, Yoko Mano, Yuri Sato, Saeko Uchida, Yoshiya Tanaka

Summary: This study aimed to analyze the pharmacokinetics (PK) of Ozoralizumab (OZR) and its correlation with clinical efficacy in rheumatoid arthritis (RA) patients. The results showed that the maximum plasma concentration (C-max) of OZR was reached in 6 days, with a half-life of 18 days. The exposure of OZR correlated negatively with patient body weight and was not significantly affected by other patient baseline characteristics. The efficacy of OZR was sustained independent of trough concentration when administered subcutaneously at a dose of 30 mg every 4 weeks for 52 weeks.

ARTHRITIS RESEARCH & THERAPY (2023)

Review Immunology

Cytokines and cytokine receptors as targets of immune-mediated inflammatory diseases-RA as a role model

Tsutomu Takeuchi

Summary: This review provides an overview of cytokines and cytokine receptors approved in immune-mediated inflammatory diseases (IMID) and discusses their role, treatment modalities, and updated molecular information in each disease, with rheumatoid arthritis as a role model.

INFLAMMATION AND REGENERATION (2022)

Article Rheumatology

Phase II/III Results of a Trial of Anti-Tumor Necrosis Factor Multivalent NANOBODY Compound Ozoralizumab in Patients With Rheumatoid Arthritis

Tsutomu Takeuchi, Masafumi Kawanishi, Megumi Nakanishi, Hironori Yamasaki, Yoshiya Tanaka

Summary: This study assessed the efficacy and safety of ozoralizumab plus methotrexate in patients with active rheumatoid arthritis. The results showed that ozoralizumab significantly reduced the signs and symptoms of RA compared to placebo, with acceptable tolerability.

ARTHRITIS & RHEUMATOLOGY (2022)

暂无数据